메뉴 건너뛰기




Volumn 75, Issue 3, 2017, Pages 271-279

Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT

(17)  Sivay, Mariya V a   Li, Maoji b   Piwowar Manning, Estelle a   Zhang, Yinfeng a   Hudelson, Sarah E a   Marzinke, Mark A a   Amico, Rivet K c   Redd, Andrew a,d   Hendrix, Craig W a   Anderson, Peter L e   Bokoch, Kevin f   Bekker, Linda Gail g   Van Griensven, Frits h   Mannheimer, Sharon i,j   Hughes, James P k   Grant, Robert l   Eshleman, Susan H a  


Author keywords

antiretroviral drugs; emtricitabine; HIV seroconverter; pre exposure prophylaxis; resistance; tenofovir

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

EID: 85015917451     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001374     Document Type: Article
Times cited : (42)

References (27)
  • 1
    • 85021327019 scopus 로고    scopus 로고
    • U. S. Food and Drug Administration. FDA-Approved HIV Medicines. 2016 accessed November 1, 2016
    • U. S. Food and Drug Administration. FDA-Approved HIV Medicines. 2016; Available at: https://aidsinfo. nih. gov/education-materials/factsheets/ 21/58/fda-approved-hiv-medicines. Accessed November 1, 2016.
  • 2
    • 84958181577 scopus 로고    scopus 로고
    • Safety of oral tenofovir disoproxil fumaratebased pre-exposure prophylaxis for HIV prevention
    • Mugwanya KK, Baeten JM. Safety of oral tenofovir disoproxil fumaratebased pre-exposure prophylaxis for HIV prevention. Expert Opin Drug Saf. 2016;15:265-273.
    • (2016) Expert Opin Drug Saf. , vol.15 , pp. 265-273
    • Mugwanya, K.K.1    Baeten, J.M.2
  • 3
    • 84944712010 scopus 로고    scopus 로고
    • HIV pre-exposure prophylaxis (PrEP): A review of current knowledge of oral systemic HIV PrEP in humans
    • Spinner CD, Boesecke C, Zink A, et al. HIV pre-exposure prophylaxis (PrEP): A review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151-158.
    • (2016) Infection. , vol.44 , pp. 151-158
    • Spinner, C.D.1    Boesecke, C.2    Zink, A.3
  • 4
    • 84965013459 scopus 로고    scopus 로고
    • Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
    • Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30: 1973-1983.
    • (2016) AIDS , vol.30 , pp. 1973-1983
    • Fonner, V.A.1    Dalglish, S.L.2    Kennedy, C.E.3
  • 5
    • 84868153362 scopus 로고    scopus 로고
    • U. S. Food and Drug Administration, http://www. fda. gov/ NewsEvents/Newsroom/PressAnnouncements/ucm312210. htm. Accessed November 1, 2016
    • U. S. Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available at: https://wayback. Archive-it. org/7993/20170112032741/http://www. fda. gov/ NewsEvents/Newsroom/PressAnnouncements/ucm312210. htm. Accessed November 1, 2016.
    • FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection.
  • 7
    • 85021369412 scopus 로고    scopus 로고
    • Center for Diseases Control, accessed November 1, 2016
    • Center for Diseases Control. New guidelines recommend daily HIV prevention pill for those at substantial risk. 2014; 67. Available at: http:// www. cdc. gov/nchhstp/newsroom/2014/PrEP-Guidelines-Press-Release. html. Accessed November 1, 2016.
    • (2014) New Guidelines Recommend Daily HIV Prevention Pill for Those at Substantial Risk , vol.67
  • 8
    • 84948822953 scopus 로고    scopus 로고
    • On-demand preexposure prophylaxis in men at high risk for HIV-1 infection
    • Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-2246.
    • (2015) N Engl J Med. , vol.373 , pp. 2237-2246
    • Molina, J.M.1    Capitant, C.2    Spire, B.3
  • 9
    • 78650549662 scopus 로고    scopus 로고
    • Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    • Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
    • (2010) N Engl J Med. , vol.363 , pp. 2587-2599
    • Grant, R.M.1    Lama, J.R.2    Anderson, P.L.3
  • 10
    • 84864507852 scopus 로고    scopus 로고
    • Preexposure prophylaxis for HIV infection among African women
    • Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
    • (2012) N Engl J Med. , vol.367 , pp. 411-422
    • Van Damme, L.1    Corneli, A.2    Ahmed, K.3
  • 11
    • 84916230041 scopus 로고    scopus 로고
    • Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: The VOICE-C qualitative study in Johannesburg, South Africa
    • van der Straten A, Stadler J, Luecke E, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: The VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(3 suppl 2):19146.
    • (2014) J Int AIDS Soc. , vol.17 , Issue.3 , pp. 19146
    • Van Der Straten, A.1    Stadler, J.2    Luecke, E.3
  • 12
    • 84950248860 scopus 로고    scopus 로고
    • Should we fear resistance from tenofovir/ emtricitabine preexposure prophylaxis
    • Parikh UM, Mellors JW. Should we fear resistance from tenofovir/ emtricitabine preexposure prophylaxis Curr Opin HIV AIDS. 2016;11: 49-55.
    • (2016) Curr Opin HIV AIDS. , vol.11 , pp. 49-55
    • Parikh, U.M.1    Mellors, J.W.2
  • 13
  • 15
    • 84991401066 scopus 로고    scopus 로고
    • A comparison of daily and nondaily preexposure prophylaxis dosing in Thai men who have sex with men, Bangkok
    • July 19-22, Vancouver, Canada. Abstract MOAC0306LB
    • Holtz TH, Chitwarakorn A, Curlin ME, et al. A comparison of daily and nondaily preexposure prophylaxis dosing in Thai men who have sex with men, Bangkok. Paper presented at: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention; July 19-22, 2015; Vancouver, Canada. Abstract MOAC0306LB.
    • (2015) 8th IAS Conference on HIV Pathogenesis Treatment and Prevention
    • Holtz, T.H.1    Chitwarakorn, A.2    Curlin, M.E.3
  • 16
    • 81055124999 scopus 로고    scopus 로고
    • Analysis of genetic linkage of HIV from couples enrolled in the HIV prevention trials network 052 trial
    • Eshleman SH, Hudelson SE, Redd AD, et al. Analysis of genetic linkage of HIV from couples enrolled in the HIV prevention trials network 052 trial. J Infect Dis. 2011;204:1918-1926.
    • (2011) J Infect Dis. , vol.204 , pp. 1918-1926
    • Eshleman, S.H.1    Hudelson, S.E.2    Redd, A.D.3
  • 17
    • 34247110127 scopus 로고    scopus 로고
    • Stanford University, accessed November 3, 2016
    • Stanford University. HIV drug resistance database. 2016; Available at: https://hivdb. stanford. edu. Accessed November 3, 2016.
    • (2016) HIV Drug Resistance Database
  • 18
    • 84886705161 scopus 로고    scopus 로고
    • Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue
    • Louissaint NA, Cao YJ, Skipper PL, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses. 2013; 29:1443-1450.
    • (2013) AIDS Res Hum Retroviruses. , vol.29 , pp. 1443-1450
    • Louissaint, N.A.1    Cao, Y.J.2    Skipper, P.L.3
  • 19
    • 79960043515 scopus 로고    scopus 로고
    • Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection
    • Bushman LR, Kiser JJ, Rower JE, et al. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011;56:390-401.
    • (2011) J Pharm Biomed Anal. , vol.56 , pp. 390-401
    • Bushman, L.R.1    Kiser, J.J.2    Rower, J.E.3
  • 20
    • 84954149594 scopus 로고    scopus 로고
    • Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066)
    • Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016;32:32-43.
    • (2016) AIDS Res Hum Retroviruses. , vol.32 , pp. 32-43
    • Hendrix, C.W.1    Andrade, A.2    Bumpus, N.N.3
  • 21
    • 84961388620 scopus 로고    scopus 로고
    • Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabinetriphosphate from erythrocytes using dried blood spots
    • Zheng JH, Rower C, McAllister K, et al. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabinetriphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016;122:16-20.
    • (2016) J Pharm Biomed Anal. , vol.122 , pp. 16-20
    • Zheng, J.H.1    Rower, C.2    McAllister, K.3
  • 22
    • 84919495524 scopus 로고    scopus 로고
    • Streamlining HIV testing for HIV preexposure prophylaxis
    • Guanira JV, Leigler T, Kallas E, et al. Streamlining HIV testing for HIV preexposure prophylaxis. J Clin Microbiol. 2015;53:179-183.
    • (2015) J Clin Microbiol. , vol.53 , pp. 179-183
    • Guanira, J.V.1    Leigler, T.2    Kallas, E.3
  • 23
    • 80051549164 scopus 로고    scopus 로고
    • Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis
    • Curtis KA, Kennedy MS, Luckay A, et al. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2011;57:355-362.
    • (2011) J Acquir Immune Defic Syndr. , vol.57 , pp. 355-362
    • Curtis, K.A.1    Kennedy, M.S.2    Luckay, A.3
  • 24
    • 85021371248 scopus 로고    scopus 로고
    • The effect of oral pre-exposure prophylaxis on the progression of HIV-1 seroconversion
    • October 17-21, Chicago, IL. Abstract OA03. 01
    • Donnell D, Ramos EM, Baeten J, et al. The effect of oral pre-exposure prophylaxis on the progression of HIV-1 seroconversion. Paper presented at: HIV Research for Prevention; October 17-21, 2016; Chicago, IL. Abstract OA03. 01.
    • (2016) HIV Research for Prevention
    • Donnell, D.1    Ramos, E.M.2    Baeten, J.3
  • 25
    • 84943327425 scopus 로고    scopus 로고
    • Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis
    • Laeyendecker O, Redd AD, Nason M, et al. Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis. J Infect Dis. 2015;212:754-759.
    • (2015) J Infect Dis. , vol.212 , pp. 754-759
    • Laeyendecker, O.1    Redd, A.D.2    Nason, M.3
  • 26
    • 84927551045 scopus 로고    scopus 로고
    • Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women
    • Grant RM, Liegler T, Defechereux P, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29:331-337.
    • (2015) AIDS , vol.29 , pp. 331-337
    • Grant, R.M.1    Liegler, T.2    Defechereux, P.3
  • 27
    • 84880070553 scopus 로고    scopus 로고
    • Cross-sectional HIV incidence estimation in HIV prevention research
    • Brookmeyer R, Laeyendecker O, Donnell D, et al. Cross-sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr. 2013;63(suppl 2):S233-S239.
    • (2013) J Acquir Immune Defic Syndr. , vol.63 , pp. S233-S239
    • Brookmeyer, R.1    Laeyendecker, O.2    Donnell, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.